Helsinn Healthcare Overview
- Year Founded
-
1976
- Status
-
Private
- Employees
-
300
- Latest Deal Type
-
PE Growth
- (Cancelled)
- Financing Rounds
-
1
- Investments
-
9
Helsinn Healthcare General Information
Description
Manufacturer and developer of late-and commercial-stage oncology products intended to cure cancer and rare diseases. The company supplies active pharmaceutical ingredients and finished dosage forms and develops medical compounds for controlling various consequences in oncology and cancer supportive care, pain, inflammation and gastrointestinal therapeutic areas, thus providing support to relieve patients with cancer of the adverse side effects of cancer treatment.
Contact Information
Website
www.helsinn.comCorporate Office
- Via Pian Scairolo 9
- Pazzallo
- 6912 Lugano
- Switzerland
Corporate Office
- Via Pian Scairolo 9
- Pazzallo
- 6912 Lugano
- Switzerland
Helsinn Healthcare Comparisons
Industry
Financing
Details
Helsinn Healthcare Competitors (60)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
LEO Pharma | Private Equity-Backed | Ballerup, Denmark | ||||
Genentech | Formerly VC-backed | South San Francisco, CA | ||||
Incyte | Formerly VC-backed | Wilmington, DE | ||||
SAGE Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
VBI Vaccines | Corporate Backed or Acquired | Cambridge, MA |
Helsinn Healthcare Patents
Helsinn Healthcare Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20220401429-A1 | Use of anamorelin to treat cancer-related fatigue | Pending | 18-Jun-2021 | ||
EP-4346820-A1 | Piperidine urea derivatives for use as inotropic agents | Pending | 02-Jun-2021 | ||
AU-2022287225-A1 | Piperidine urea derivatives for use as inotropic agents | Pending | 02-Jun-2021 | ||
CA-3221574-A1 | Piperidine urea derivatives for use as inotropic agents | Pending | 02-Jun-2021 | ||
US-20240277688-A1 | Piperidine urea derivatives for use as inotropic agents | Pending | 02-Jun-2021 | A61K31/4468 |
Helsinn Healthcare Signals
Helsinn Healthcare Subsidiaries (1)
Company Name | Industry | Location | Founded |
---|---|---|---|
3B Future Health Fund | Venture Capital | Monte Carlo, Monaco |
Helsinn Healthcare Exits (2)
Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
---|---|---|---|---|---|
Aadi Bioscience | 08-May-2017 | Completed |
|
||
Thorne Research | 17-May-2011 | PE Growth/Expansion | Completed |
Helsinn Healthcare FAQs
-
When was Helsinn Healthcare founded?
Helsinn Healthcare was founded in 1976.
-
Where is Helsinn Healthcare headquartered?
Helsinn Healthcare is headquartered in Lugano, Switzerland.
-
What is the size of Helsinn Healthcare?
Helsinn Healthcare has 300 total employees.
-
What industry is Helsinn Healthcare in?
Helsinn Healthcare’s primary industry is Pharmaceuticals.
-
Is Helsinn Healthcare a private or public company?
Helsinn Healthcare is a Private company.
-
What is Helsinn Healthcare’s current revenue?
The current revenue for Helsinn Healthcare is
. -
Who are Helsinn Healthcare’s competitors?
LEO Pharma, Genentech, Incyte, SAGE Therapeutics, and VBI Vaccines are some of the 60 competitors of Helsinn Healthcare.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »